導(dǎo)師簡(jiǎn)介

姓名：張曉東 性別：男 政治面貌：群眾 學(xué)歷：研究生 學(xué)位： 醫(yī)學(xué)博士 職稱：主任醫(yī)師

博、碩導(dǎo)師：碩導(dǎo) 本崗位工作年數(shù)：28年

研究方向：慢性腎臟病防治

榮譽(yù)稱號(hào)：無(wú)

學(xué)術(shù)任職：目前擔(dān)任《中國(guó)中西醫(yī)結(jié)合腎病雜志》編委；山西醫(yī)學(xué)會(huì)腎病分會(huì)副主委；中華老年醫(yī)學(xué)腎病學(xué)組委員；中國(guó)醫(yī)師協(xié)會(huì)中西醫(yī)結(jié)合分會(huì)全國(guó)委員；中國(guó)醫(yī)師協(xié)會(huì)山西中西醫(yī)結(jié)合分會(huì)副會(huì)長(zhǎng)；中國(guó)醫(yī)師協(xié)會(huì)山西腎病分會(huì)常務(wù)委員；中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)山西腎病分會(huì)委員；。

近五年承擔(dān)科研課題情況：

(1)山西省科技廳,自然科學(xué)研究面上項(xiàng)目, 202403021211152,益腎膠囊上調(diào)SIRT6/HIF-1a信號(hào)通路改善糖尿病腎病腎小管上皮細(xì)胞焦亡的機(jī)制, 2024-07至2027-07,在研,主持

(2)山西省科技廳,自然科學(xué)研究面上項(xiàng)目, 202303021211205,黃芪甲苷調(diào)節(jié)HIF-1α介導(dǎo)的自噬改善腹膜透析相關(guān)腹膜纖維化的機(jī)制研究, 2024-01至2026-12,在研,參與

代表性論著及近五年的代表性論文（限10項(xiàng)以內(nèi)）：

1.Liu T, Cao Y, Liang N, Ma X, Fang JA, Zhang X. Investigating the causal association between gut microbiota and type 2 diabetes: a meta-analysis and Mendelian randomization. Front Public Health. 2024 Jun 19;12:1342313.

2.Liu T, Li R, Wang X, Gao X, Zhang X. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis. Med Clin (Barc). 2022 Jul 22;159(2):65-72.

3.Liu T, Wang X, Li R, Zhang ZY, Fang J, Zhang X. Effects of Probiotic Preparations on Inflammatory Cytokines in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Curr Pharm Biotechnol. 2021;22(10):1338-1349.

4.Cao Y, Liang N, Kong K, Qiao X, Liu T, Fang JA, Zhang X. CD163 as a Potential Biomarker-associated Immune Inflammation in Diabetes Mellitus: A Systematic Review and Bioinformatics Analysis. Endocr Metab Immune Disord Drug Targets. 2024;24(2):208-219.

5.Liang N, Ma X, Cao Y, Liu T, Fang JA, Zhang X. Mendelian Randomization Studies: Opening a New Window in the Study of Metabolic Diseases and Chronic Kidney Disease. Endocr Metab Immune Disord Drug Targets. 2024 Aug 20. doi: 10.2174/0118715303288685240808073238.

6.Qiao X, Kong K, Liu T, Jia Y, Fang J, Zhang X. Gut-Skin Axis: Unravelling the Link Between Gut Microbiome and Chronic Kidney Disease-Related Skin Lesions. Endocr Metab Immune Disord Drug Targets. 2024;24(1):39-49.

7.Kong K, Qiao X, Liu T, Wang X, Li R, Fang J, Zhang X. Identification of Novel Hub Genes Associated with Inflammation and Autophagy in Astragaloside Membranaceus ameliorates Lupus Nephritis by Bioinformatics Analysis and Molecular Dynamics Simulation. Comb Chem High Throughput Screen. 2025;28(2):306-318.

8.Cao Y, Liang N, Liu T, Fang J, Zhang X. Effect of SGLT2 Inhibitors and Metformin on Inflammatory and Prognostic Biomarkers in Type 2 Diabetes Patients. Endocr Metab Immune Disord Drug Targets. 2023;23(4):530-547.

9.Liu Y, Liu W, Zhang Z, Hu Y, Zhang X, Sun Y, Lei Q, Sun D, Liu T, Fan Y, Li H, Ding W, Fang J. Yishen capsule promotes podocyte autophagy through regulating SIRT1/NF-κB signaling pathway to improve diabetic nephropathy. Ren Fail. 2021 Dec;43(1):128-140.

10.Wang X, Li R, Liu T, Jia Y, Gao X, Zhang X.CD163in Macrophages: A Potential Biomarker for Predicting the Progression of Diabetic Nephropathy based on Bioinformatics Analysis. Endocr Metab Immune Disord Drug Targets. 2023;23(3):294-303.